HUBEI PROVINCE, China--(BUSINESS WIRE)--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTC BB: BPMA), a China-based pharmaceutical company producing both Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, announced today it realized a total of $3.3 MM in revenue through December 2007 from the previously reported $3.8 MM in combined Gendicine® orders generated at China’s September 2007 national biotechnology conference.
